Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Identification of HSP90 inhibitors as a novel class of senolytics

Open access

Abstract

Aging is the main risk factor for many chronic degenerative diseases and cancer. Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases. Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty and improving stem cell function in multiple murine models of aging. To identify novel and more optimal senotherapeutic drugs and combinations, we established a senescence associated β-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells. We used primary Ercc1 −/− murine embryonic fibroblasts with reduced DNA repair capacity, which senesce rapidly if grown at atmospheric oxygen. This platform was used to screen a small library of compounds that regulate autophagy, identifying two inhibitors of the HSP90 chaperone family as having significant senolytic activity in mouse and human cells. Treatment of Ercc1 −/∆ mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan, delayed the onset of several age-related symptoms and reduced p16 INK4a expression. These results demonstrate the utility of our screening platform to identify senotherapeutic agents as well as identified HSP90 inhibitors as a promising new class of senolytic drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-00314-z

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Development of a novel assay to screen for senotherapeutics. a Schematic diagram of the assay. Passage 2 primary mouse embryonic fibroblasts MEFs from DNA repair-deficient Ercc1 −/− mice are passaged at 20% O2 to induce oxidative DNA damage. After 3 passages, 50% of the cells are senescent (red) and 50% remain non-senescent (yellow). Drugs are tested on these mixed cultures to determine if they affect senescent (C12FDG positive) or non-senescent (C12FDG negative) cells. b Representative images derived from three replicate experiments of p5 Ercc1 −/− MEF cultures measuring senescence-associated b-gal (SA-β-Gal) activity using colorimetric X-gal staining. Scale bar, 50 μm. c Representative flow cytometric histogram detecting SA-β-Gal activity using C12FDG in senescent and non-senescent Ercc1 −/− MEF populations. The dotted line indicates the cut-off in intensity levels used to define senescent cells. d Representative image from IN Cell Analyzer 6000 to detect SA-β-Gal in p5 Ercc1 −/− MEFs using C12FDG. Senescent cells are outlined in red (S), non-senescent cells are outlined in yellow (NS) and blue fluorescence indicates Hoechst-stained DNA in nuclei (N) used to obtain a total cell count. Scale bar, 50 μm. e Quantification of the senescent cell population in non-senescent (NS) and senescent (S) p5 Ercc1 −/− MEF cell cultures detected with X-gal and with C12FDG by flow cytometry and INCell 6000 analyzer. Error bars indicate SD for n = 3. *p < 0.05, two-tailed Student’s t-test
Fig. 1 Development of a novel assay to screen for senotherapeutics. a Schematic diagram of the assay. Passage 2 primary mouse embryonic fibroblasts MEFs from DNA repair-deficient Ercc1 −/− mice are passaged at 20% O2 to induce oxidative DNA damage. After 3 passages, 50% of the cells are senescent (red) and 50% remain non-senescent (yellow). Drugs are tested on these mixed cultures to determine if they affect senescent (C12FDG positive) or non-senescent (C12FDG negative) cells. b Representative images derived from three replicate experiments of p5 Ercc1 −/− MEF cultures measuring senescence-associated b-gal (SA-β-Gal) activity using colorimetric X-gal staining. Scale bar, 50 μm. c Representative flow cytometric histogram detecting SA-β-Gal activity using C12FDG in senescent and non-senescent Ercc1 −/− MEF populations. The dotted line indicates the cut-off in intensity levels used to define senescent cells. d Representative image from IN Cell Analyzer 6000 to detect SA-β-Gal in p5 Ercc1 −/− MEFs using C12FDG. Senescent cells are outlined in red (S), non-senescent cells are outlined in yellow (NS) and blue fluorescence indicates Hoechst-stained DNA in nuclei (N) used to obtain a total cell count. Scale bar, 50 μm. e Quantification of the senescent cell population in non-senescent (NS) and senescent (S) p5 Ercc1 −/− MEF cell cultures detected with X-gal and with C12FDG by flow cytometry and INCell 6000 analyzer. Error bars indicate SD for n = 3. *p < 0.05, two-tailed Student’s t-testCC BY · PubMed Central
Fig. 2 Detection of senescence markers in Ercc1 −/− MEFs. a Cell proliferation was measured in congenic WT and Ercc1 −/− MEFs from p2 through p5. n = 2. b Relative expression of p21Cip1 and c p16INK4a in p2 non-senescent (NS) and p5 senescent (S) Ercc1 −/− MEFs determined by qRT-PCR. Error bars indicate SD for n = 3. *p < 0.05, two-tailed Student’s t-test. d Protein expression levels of γH2AX in p2 NS and p5 S Ercc1 −/− MEFs. Changes in diameter e and volume f in p2 NS and p5 S Ercc1 −/− MEFs. Error bars indicate SD for n=3. * p < 0.05, two-tailed Student’s t-test. Ratio of cells expressing p16INK4a g and IL-6 h in p2 NS and p5 S cultures determined by ViewRNA fluorescence in situ hybridization. Error bars indicate SD for n ⩾ =2. * p < 0.05, two-tailed Student’s t-test. i Representative FISH image of p16INK4a and IL-6 of passage 5 S Ercc1 −/− MEFs
Fig. 2 Detection of senescence markers in Ercc1 −/− MEFs. a Cell proliferation was measured in congenic WT and Ercc1 −/− MEFs from p2 through p5. n = 2. b Relative expression of p21Cip1 and c p16INK4a in p2 non-senescent (NS) and p5 senescent (S) Ercc1 −/− MEFs determined by qRT-PCR. Error bars indicate SD for n = 3. *p < 0.05, two-tailed Student’s t-test. d Protein expression levels of γH2AX in p2 NS and p5 S Ercc1 −/− MEFs. Changes in diameter e and volume f in p2 NS and p5 S Ercc1 −/− MEFs. Error bars indicate SD for n=3. * p < 0.05, two-tailed Student’s t-test. Ratio of cells expressing p16INK4a g and IL-6 h in p2 NS and p5 S cultures determined by ViewRNA fluorescence in situ hybridization. Error bars indicate SD for n ⩾ =2. * p < 0.05, two-tailed Student’s t-test. i Representative FISH image of p16INK4a and IL-6 of passage 5 S Ercc1 −/− MEFsCC BY · PubMed Central
Fig. 3 Characterization of a novel, C12FDG single-cell SA-ß-gal drug screening assay. a Scheme of possible outcomes after treating a senescent p5 Ercc1 −/− MEF culture with a potential senotherapeutic. Red=senescent cells, yellow=non-senescent cells. Senotherapeutics are characterized by either killing of senescent cells (senolytics) or by altering the senescent state of cells otherwise (senomorphics). After 48 h treating p5 senescent Ercc1 −/− MEFs with a drug, the relative number of senescent cells b and total cells c remaining is quantitated and plotted relative to untreated control cultures. Red bars indicate relative number of senescent cells, grey bars indicate relative number of total cells. Error bars indicate SD for n = 3. *p < 0.05 for senescent cells, two-tailed Student’s t-test
Fig. 3 Characterization of a novel, C12FDG single-cell SA-ß-gal drug screening assay. a Scheme of possible outcomes after treating a senescent p5 Ercc1 −/− MEF culture with a potential senotherapeutic. Red=senescent cells, yellow=non-senescent cells. Senotherapeutics are characterized by either killing of senescent cells (senolytics) or by altering the senescent state of cells otherwise (senomorphics). After 48 h treating p5 senescent Ercc1 −/− MEFs with a drug, the relative number of senescent cells b and total cells c remaining is quantitated and plotted relative to untreated control cultures. Red bars indicate relative number of senescent cells, grey bars indicate relative number of total cells. Error bars indicate SD for n = 3. *p < 0.05 for senescent cells, two-tailed Student’s t-testCC BY · PubMed Central
Fig. 4 Screening of a library of autophagy regulators yields senolytics. a Pie chart indicating the different functional groups of drugs in the autophagy library used in the screen. b The primary screen of all 97 autophagy regulators at 1 mM concentration. Plotted on the x-axis is the number of senescent cells in the drug-treated cultures relative to cells treated with vehicle only. On the y-axis is the fraction of total cells remaining after drug treatment relative to vehicle treated controls. Drugs that reduce the number of senescent cells > 50% can be found in the blue shaded area. Drugs that cause no change in cell number (senomorphics) are indicated by blue dots. Drugs that caused a decrease in total cell number to < 75% (potential senolytics) are indicated in red. Grey dots indicate drugs that lead to no significant change in cell senescence at the concentration used. c Pie chart indicating the functional groups of potential senescence-modulating drugs identified in the autophagy library. d Independent validation of the primary screen expressed as cell senescence and cell number relative to untreated control cultures (UT) of senescent cells. Known lysosomal inhibitors (lysosomal pH changing compounds, Fig. 4C) were excluded. All drugs were used at 1 μM, n = 3, graphed + SD. *p < 0.05, two-tailed Student’s t-test
Fig. 4 Screening of a library of autophagy regulators yields senolytics. a Pie chart indicating the different functional groups of drugs in the autophagy library used in the screen. b The primary screen of all 97 autophagy regulators at 1 mM concentration. Plotted on the x-axis is the number of senescent cells in the drug-treated cultures relative to cells treated with vehicle only. On the y-axis is the fraction of total cells remaining after drug treatment relative to vehicle treated controls. Drugs that reduce the number of senescent cells > 50% can be found in the blue shaded area. Drugs that cause no change in cell number (senomorphics) are indicated by blue dots. Drugs that caused a decrease in total cell number to < 75% (potential senolytics) are indicated in red. Grey dots indicate drugs that lead to no significant change in cell senescence at the concentration used. c Pie chart indicating the functional groups of potential senescence-modulating drugs identified in the autophagy library. d Independent validation of the primary screen expressed as cell senescence and cell number relative to untreated control cultures (UT) of senescent cells. Known lysosomal inhibitors (lysosomal pH changing compounds, Fig. 4C) were excluded. All drugs were used at 1 μM, n = 3, graphed + SD. *p < 0.05, two-tailed Student’s t-testCC BY · PubMed Central
Fig. 5 HSP90 inhibitors selectively kill senescent cells. a, b Celltox Green cytotoxicity assay. All potential senolytic drugs were added to cultures of a non-senescent (confluent) wild-type and b senescent Ercc1 −/− primary MEFs at 4 concentrations (0.03–1.00 μM). Error bars indicate SD for n = 3. c Graph depicting drugs that specifically kill senescent cells. Plotted is the viability of non-senescent WT vs. senescent Ercc1 −/− cells after treatment with each drug for 48 h at a 1 μM concentration. Cell toxicity was defined as cell viability < 75%. Only cells that kill senescent cells, without significant toxicity to quiescent, non-senescent cells, are considered as senolytics (indicated in yellow shaded area). d Dose response analysis of senolytic activity of 17-DMAG. Increasing concentrations of 17-DMAG (0.1–1000 nM) were tested and plotted against the fraction of remaining senescent (red) and non-senescent cells (yellow) after 48 h treatment. The EC50 values of their senolytic potential were determined from their dose response curves using a 4-parameter curve fit analysis (graphpad). Error bars indicate SD for n = 3. e Flow cytometric analysis of cell death of senescent Ercc1 −/− MEF cell cultures treated with 17-DMAG via AnnexinV/7-AAD staining. MEF cells are either senescent (C12FDG+; Top) or non-senescent (C12FDG−, Bottom). Live cells were double negative for 7-AAD and AnnexinV (bottom left quadrant), early apoptotic cells were positive for Annexin V (bottom right quadrant), late apoptotic cells were positive for AnnexinV and 7-AAD (top left quadrant) and dead cells were positive for 7-AAD only (bottom right quadrant). f Quantification of the flow cytometry data. Apoptosis of senescent (red) and non-senescent (yellow) cells was calculated by summing up all AnnexinV-positive cells. Error bars indicate SD for n = 3, *p < 0.05, two-tailed Student’s t-test
Fig. 5 HSP90 inhibitors selectively kill senescent cells. a, b Celltox Green cytotoxicity assay. All potential senolytic drugs were added to cultures of a non-senescent (confluent) wild-type and b senescent Ercc1 −/− primary MEFs at 4 concentrations (0.03–1.00 μM). Error bars indicate SD for n = 3. c Graph depicting drugs that specifically kill senescent cells. Plotted is the viability of non-senescent WT vs. senescent Ercc1 −/− cells after treatment with each drug for 48 h at a 1 μM concentration. Cell toxicity was defined as cell viability < 75%. Only cells that kill senescent cells, without significant toxicity to quiescent, non-senescent cells, are considered as senolytics (indicated in yellow shaded area). d Dose response analysis of senolytic activity of 17-DMAG. Increasing concentrations of 17-DMAG (0.1–1000 nM) were tested and plotted against the fraction of remaining senescent (red) and non-senescent cells (yellow) after 48 h treatment. The EC50 values of their senolytic potential were determined from their dose response curves using a 4-parameter curve fit analysis (graphpad). Error bars indicate SD for n = 3. e Flow cytometric analysis of cell death of senescent Ercc1 −/− MEF cell cultures treated with 17-DMAG via AnnexinV/7-AAD staining. MEF cells are either senescent (C12FDG+; Top) or non-senescent (C12FDG−, Bottom). Live cells were double negative for 7-AAD and AnnexinV (bottom left quadrant), early apoptotic cells were positive for Annexin V (bottom right quadrant), late apoptotic cells were positive for AnnexinV and 7-AAD (top left quadrant) and dead cells were positive for 7-AAD only (bottom right quadrant). f Quantification of the flow cytometry data. Apoptosis of senescent (red) and non-senescent (yellow) cells was calculated by summing up all AnnexinV-positive cells. Error bars indicate SD for n = 3, *p < 0.05, two-tailed Student’s t-testCC BY · PubMed Central
Fig. 6 HSP90 inhibitors (HSP90inhs) are senolytic in two species and multiple cell types. a, b Representative dose response curves of seven HSP90 inhibitors. Eight concentrations (0.1–1000 nM) of each drug were tested and plotted against the relative fraction of remaining senescent a and non-senescent passage 5 ERCC-deficient MEFs b to determine their senolytic and cytotoxic potential. c Structure, origin, and IC50 (HSP90a/b inhibition) of the HSP90 inhibitors tested in (A and B). EC50 values of their cytotoxic potential for senescent (sen) and non-senescent (non-sen) cells were determined from their dose response curves in A and B using a 3-parameter curve fit analysis (graphpad), n = 2. d Effect of 17-DMAG on multiple cell types. Cell senescence was measured after treatment of senescent cultures of two different types of mouse cell (MEFs and mesenchymal stem cells) and two different human cell types (IMR90 primary myofibroblasts and WI38 primary lung fibroblasts) with 100 nM 17-DMAG. Senescence was induced by three methods: oxidative stress (murine cells), genotoxic stress (etoposide IMR90), and replicative stress (WI38, passage 30). All experiments were performed in triplicate. Error bars indicate SD, *p < 0.05, two-tailed Student’s t-test. e Viability of HUVECs (human umbilical vein endothelial cells) treated with the HSP90 inhibitor ganetespib. Proliferating and senescent HUVECs were exposed to different concentrations of ganetespib (5–800 nM). After 72 h, the number of viable cells was measured. The red line denotes plating densities on day 0 of non-dividing senescent (set to 100%) as well as proliferating, non-senescent cells (also set to 100%). Plotted are the means ± SEM of five replicates at each concentration. Senescence was induced by 10 Gy ionizing radiation
Fig. 6 HSP90 inhibitors (HSP90inhs) are senolytic in two species and multiple cell types. a, b Representative dose response curves of seven HSP90 inhibitors. Eight concentrations (0.1–1000 nM) of each drug were tested and plotted against the relative fraction of remaining senescent a and non-senescent passage 5 ERCC-deficient MEFs b to determine their senolytic and cytotoxic potential. c Structure, origin, and IC50 (HSP90a/b inhibition) of the HSP90 inhibitors tested in (A and B). EC50 values of their cytotoxic potential for senescent (sen) and non-senescent (non-sen) cells were determined from their dose response curves in A and B using a 3-parameter curve fit analysis (graphpad), n = 2. d Effect of 17-DMAG on multiple cell types. Cell senescence was measured after treatment of senescent cultures of two different types of mouse cell (MEFs and mesenchymal stem cells) and two different human cell types (IMR90 primary myofibroblasts and WI38 primary lung fibroblasts) with 100 nM 17-DMAG. Senescence was induced by three methods: oxidative stress (murine cells), genotoxic stress (etoposide IMR90), and replicative stress (WI38, passage 30). All experiments were performed in triplicate. Error bars indicate SD, *p < 0.05, two-tailed Student’s t-test. e Viability of HUVECs (human umbilical vein endothelial cells) treated with the HSP90 inhibitor ganetespib. Proliferating and senescent HUVECs were exposed to different concentrations of ganetespib (5–800 nM). After 72 h, the number of viable cells was measured. The red line denotes plating densities on day 0 of non-dividing senescent (set to 100%) as well as proliferating, non-senescent cells (also set to 100%). Plotted are the means ± SEM of five replicates at each concentration. Senescence was induced by 10 Gy ionizing radiationCC BY · PubMed Central
Fig. 7 Multiple senescence markers are reduced in Ercc1 −/− MEFs after treatment with HSP90 inhibitors. a Diameter and volume of senescent Ercc1 −/− MEF cells were measured before (red) and after (orange) 1 µM 17-DMAG (17D) treatment for 24 h. Error bars indicate SD for n = 3, *p < 0.05, two-tailed Student’s t-test. b Relative mRNA expression of IL-6 and p16INK4a determined by qRT-PCR was measured in untreated (UT) and 17-DMAG (17D) treated cells for 24 h. Error bars indicate SD for n = 3. * p < 0.05, two-tailed Student’s t-test. c Representative FISH images of p16INK4a (green) and IL-6 (red) in senescent Ercc1 −/− MEFs with (17D) and without (UT) 17-DMAG treatment. d Quantification of the fraction of cells expressing p16INK4a and IL-6 in p5 Ercc1 −/− MEF cells with (orange) and without (red) 17-DMAG treatment for 24 h determined by ViewRNA FISH. Error bars indicate SD for n = 2. *p < 0.05, two-tailed Student’s t-test. e Immunoblot detection of the DNA damage/senescence marker γH2AX in p5 Ercc1 −/− MEF cultures at several time points following exposure to 100 nM 17-DMAG. Semi-quantitative analysis of γH2AX expression relative to β-actin. Western blots were quantified with ImageJ
Fig. 7 Multiple senescence markers are reduced in Ercc1 −/− MEFs after treatment with HSP90 inhibitors. a Diameter and volume of senescent Ercc1 −/− MEF cells were measured before (red) and after (orange) 1 µM 17-DMAG (17D) treatment for 24 h. Error bars indicate SD for n = 3, *p < 0.05, two-tailed Student’s t-test. b Relative mRNA expression of IL-6 and p16INK4a determined by qRT-PCR was measured in untreated (UT) and 17-DMAG (17D) treated cells for 24 h. Error bars indicate SD for n = 3. * p < 0.05, two-tailed Student’s t-test. c Representative FISH images of p16INK4a (green) and IL-6 (red) in senescent Ercc1 −/− MEFs with (17D) and without (UT) 17-DMAG treatment. d Quantification of the fraction of cells expressing p16INK4a and IL-6 in p5 Ercc1 −/− MEF cells with (orange) and without (red) 17-DMAG treatment for 24 h determined by ViewRNA FISH. Error bars indicate SD for n = 2. *p < 0.05, two-tailed Student’s t-test. e Immunoblot detection of the DNA damage/senescence marker γH2AX in p5 Ercc1 −/− MEF cultures at several time points following exposure to 100 nM 17-DMAG. Semi-quantitative analysis of γH2AX expression relative to β-actin. Western blots were quantified with ImageJCC BY · PubMed Central
Fig. 8 Expression of heat shock proteins and HSP90 client proteins in senescent and non-senescent Ercc1 -/- MEFs. a Proposed model for how HSP90 promotes resistance to apoptosis in senescent, p5 Ercc1 −/− MEFs. b Immunoblot detection of HSP90, pAKT (Ser473), AKT, and actin in early passage, non-senescent cells (NS), intermediate passage (I), and late passage, senescent Ercc1-deficient MEFs (S) grown at 20% O2. c Immunoblot detection of the same proteins in senescent, p5 Ercc1 −/− MEFs treated with 100 nM 17-DMAG at 6 and 24 h post-treatment
Fig. 8 Expression of heat shock proteins and HSP90 client proteins in senescent and non-senescent Ercc1 -/- MEFs. a Proposed model for how HSP90 promotes resistance to apoptosis in senescent, p5 Ercc1 −/− MEFs. b Immunoblot detection of HSP90, pAKT (Ser473), AKT, and actin in early passage, non-senescent cells (NS), intermediate passage (I), and late passage, senescent Ercc1-deficient MEFs (S) grown at 20% O2. c Immunoblot detection of the same proteins in senescent, p5 Ercc1 −/− MEFs treated with 100 nM 17-DMAG at 6 and 24 h post-treatmentCC BY · PubMed Central
Fig. 9 Intermittent treatment of progeroid Ercc1 −/Δ mice with the senolytic HSP90 inhibitor 17-DMAG extends healthspan. a Schematic diagram of the in vivo treatment regiment. Animals were treated with 10 mg/kg 17-DMAG by oral gavage 3 times per week, every 3 weeks. Eight symptoms associated with frailty and aging were measured in the mice, 3 times each week. b Graphed is the age at onset of each symptom (appearance of a colored bar) and severity (height of the bar) for a sex-matched sibling pair of Ercc1 −/Δ mice treated with or without 17-DMAG. The composite height of the bar is an indication of the overall health (i.e., body condition score with a higher value being worse). c Comparison of age-related symptoms between cohorts of mice treated with the HSP90 inhibitor or vehicle only over time. The average fraction of total symptoms appearing in each age group is plotted. An increase in the percent of symptoms indicates a decrease in health. n = 6 mice per treatment group, error bars indicate SEM, *p < 0.05, **p < 0.01, ***p < 0.001. Relative expression levels of p16INK4a in kidney d and liver e of Ercc1 −/Δ mice treated for 1 week by oral gavage with HSP90 inhibitor (10 mg/kg 17-DMAG oral gavage per treatment, 3×) compared to vehicle only. p16INK4a was measured by qRT-PCR. n = 4 mice per group; error bars indicate SD, *p < 0.05, two tailed Student t-test
Fig. 9 Intermittent treatment of progeroid Ercc1 −/Δ mice with the senolytic HSP90 inhibitor 17-DMAG extends healthspan. a Schematic diagram of the in vivo treatment regiment. Animals were treated with 10 mg/kg 17-DMAG by oral gavage 3 times per week, every 3 weeks. Eight symptoms associated with frailty and aging were measured in the mice, 3 times each week. b Graphed is the age at onset of each symptom (appearance of a colored bar) and severity (height of the bar) for a sex-matched sibling pair of Ercc1 −/Δ mice treated with or without 17-DMAG. The composite height of the bar is an indication of the overall health (i.e., body condition score with a higher value being worse). c Comparison of age-related symptoms between cohorts of mice treated with the HSP90 inhibitor or vehicle only over time. The average fraction of total symptoms appearing in each age group is plotted. An increase in the percent of symptoms indicates a decrease in health. n = 6 mice per treatment group, error bars indicate SEM, *p < 0.05, **p < 0.01, ***p < 0.001. Relative expression levels of p16INK4a in kidney d and liver e of Ercc1 −/Δ mice treated for 1 week by oral gavage with HSP90 inhibitor (10 mg/kg 17-DMAG oral gavage per treatment, 3×) compared to vehicle only. p16INK4a was measured by qRT-PCR. n = 4 mice per group; error bars indicate SD, *p < 0.05, two tailed Student t-testCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

19 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

See all 740

Metadata

Authors
Fuhrmann-Stroissnigg, H., Ling, Y. Y., Zhao, J., McGowan, S. J., Zhu, Y., Brooks, R. W., Grassi, D., Gregg, S. Q., Stripay, J. L., Dorronsoro, A., Corbo, L., Tang, P., Bukata, C., Ring, N., Giacca, M., Li, X., Tchkonia, T., Kirkland, J. L., Niedernhofer, L. J., & Robbins, P. D.
Affiliations
  • Scripps Research Institute (US)
  • University of Pittsburgh (US)
  • Mayo Clinic (US)
  • International Centre for Genetic Engineering and Biotechnology (IT)
Corresponding author
Robbins, Paul D.
Venue
Nature Communications
Published
2017-09-04
Volume
8
Issue
1
Pages
422-422
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2752676842
Cited by
701
References
77
Citations by year
2026: 58 · 2025: 70 · 2024: 94 · 2023: 68 · 2022: 102 · 2021: 95 · 2020: 89 · 2019: 68 · 2018: 49 · 2017: 6
FWCI
42.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • American Federation for Aging Research
  • National Institutes of Health (DK-50456, AG043376, AG13925)
  • National Institute on Aging (P01AG043376, R01AG013925, R37AG013925)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK050456)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords
Hsp90 inhibitors, senolytics, cellular senescence, senotherapeutics, aging, autophagy, 17-DMAG, healthspan, progeroid syndromes, p16INK4a, drug screening
MeSH terms
Aging, Animals, Autophagy, Biological Assay, DNA-Binding Proteins, Drug Evaluation, Preclinical, Endonucleases, Female, Fibroblasts, Humans, Signal Transduction, Biomarkers, Down-Regulation, Benzoquinones, Cellular Senescence, Apoptosis, HSP90 Heat-Shock Proteins, Phosphatidylinositol 3-Kinases, Lactams, Macrocyclic, Proto-Oncogene Proteins c-akt, Mice, Small Molecule Libraries, Human Umbilical Vein Endothelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of HSP90 inhibitors as a novel class of senolytics. https://app.cochat.ai/papers/10.1038/s41467-017-00314-z
The paper
Fuhrmann-Stroissnigg, H., Ling, Y. Y., Zhao, J., McGowan, S. J., Zhu, Y., Brooks, R. W., Grassi, D., Gregg, S. Q., Stripay, J. L., Dorronsoro, A., Corbo, L., Tang, P., Bukata, C., Ring, N., Giacca, M., Li, X., Tchkonia, T., Kirkland, J. L., Niedernhofer, L. J., & Robbins, P. D. (2017). Identification of HSP90 inhibitors as a novel class of senolytics. Nature Communications. https://doi.org/10.1038/s41467-017-00314-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.